Instylla HES Hypervascular Tumor Pivotal Study
NCT: NCT04523350 · COMPLETED
Brief Summary
To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional transarterial chemoembolization, while resulting in an acceptable risk of device and procedure-related serious adverse events.
Frequently Asked Questions
What is Instylla HES Hypervascular Tumor Pivotal Study?
Instylla HES Hypervascular Tumor Pivotal Study is a clinical trial registered under NCT04523350. Current status: COMPLETED.
What is the status of NCT04523350?
The current status of NCT04523350 (Instylla HES Hypervascular Tumor Pivotal Study) is: COMPLETED.
When did Instylla HES Hypervascular Tumor Pivotal Study start?
Instylla HES Hypervascular Tumor Pivotal Study started on 2021-03-05.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.